Roivant Sciences (Roivant Sciences) Days Sales Outstanding : 114.49 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Roivant Sciences Days Sales Outstanding?

Roivant Sciences's average Accounts Receivable for the three months ended in Dec. 2023 was $46.6 Mil. Roivant Sciences's Revenue for the three months ended in Dec. 2023 was $37.1 Mil. Hence, Roivant Sciences's Days Sales Outstanding for the three months ended in Dec. 2023 was 114.49.

The historical rank and industry rank for Roivant Sciences's Days Sales Outstanding or its related term are showing as below:

ROIV' s Days Sales Outstanding Range Over the Past 10 Years
Min: 25.6 Med: 63.81 Max: 111.72
Current: 111.72

During the past 3 years, Roivant Sciences's highest Days Sales Outstanding was 111.72. The lowest was 25.60. And the median was 63.81.

ROIV's Days Sales Outstanding is ranked worse than
70.11% of 890 companies
in the Biotechnology industry
Industry Median: 72.665 vs ROIV: 111.72

Roivant Sciences's Days Sales Outstanding declined from Dec. 2022 (141.82) to Dec. 2023 (114.49).

Warning Sign:

If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.

Roivant Sciences Days Sales Outstanding Historical Data

The historical data trend for Roivant Sciences's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roivant Sciences Days Sales Outstanding Chart

Roivant Sciences Annual Data

Trend

Mar21

Mar22

Mar23

Days Sales Outstanding

25.60

102.02

Roivant Sciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial										141.82	97.24	142.30	109.67	114.49

Competitive Comparison of Roivant Sciences's Days Sales Outstanding

For the Biotechnology subindustry, Roivant Sciences's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Roivant Sciences's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Roivant Sciences's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Roivant Sciences's Days Sales Outstanding falls into.

Roivant Sciences Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Roivant Sciences's Days Sales Outstanding for the fiscal year that ended in Mar. 2023 is calculated as

	Days Sales Outstanding (A: Mar. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Mar. 2022 )	+	Accounts Receivable (A: Mar. 2023 ))	/	count )	/	Revenue (A: Mar. 2023 )	*	Days in Period
=	( (3.878	+	30.379)	/	2 )	/	61.28	*	365
=	17.1285					/	61.28	*	365
=	102.02

Roivant Sciences's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (52.118	+	41.078)	/	2 )	/	37.14	*	365 / 4
=	46.598					/	37.14	*	365 / 4
=	114.49

Roivant Sciences (NAS:ROIV) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Roivant Sciences Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Roivant Sciences's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Roivant Sciences (Roivant Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roivant Sciences Ltd (NAS:ROIV) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

87S:Germany

Address

50 Broadway, 7th Floor, London, GBR, SW1H 0BD

Website

https://www.roivant.com

Roivant Sciences Ltd is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients.

Executives

Eric Venker	officer: President & COO	C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
Keith S Manchester	director	C/O ROIVANT SCIENCES LTD., 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FL, LONDON X0 SW1Y 4L
Daniel Allen Gold	director	6720 VIA AUSTI PARKWAY, SUITE 450, LAS VEGAS NV 89119
Qvt Financial Lp	10 percent owner, other: Director by Deputization	888 SEVENTH AVENUE, 43RD FLOOR, NEW YORK NY 10106
Svf Investments (uk) Ltd	10 percent owner	69 GROSVENOR STREET, LONDON X0 W1K3JP
Rakhi Kumar	officer: Chief Accounting Officer	C/O NEUROPACE INC, 455 N BERNARDO AVENUE, MOUNTAIN VIEW CA 94043
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Performance Llc	10 percent owner	55 RAILROAD AVENUE, 3RD FLOOR, GREENWICH CT 06830
Sumitomo Chemical Co., Ltd.	10 percent owner	7-1, NIHONBASHI 2-CHOME, CHUO-KU, TOKYO M0 103-6020
Viking Global Opportunities Parent Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Softbank Vision Fund L.p.	10 percent owner	AZTEC GROUP HOUSE, 11-15 SEATON PLACE, ST HELIER Y9 JE4 0QH
Meghan Fitzgerald	director	C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Richard Pulik	officer: CFO	SUITE 1, 3RD FLOOR, 11-12 ST. JAMES'S SQUARE, LONDON X0 SW1Y 4LB
Vivek Ramaswamy	director	C/O ONCORE BIOPHARMA, INC., 3805 OLD EASTON ROAD, DOYLESTOWN PA 18902
Dexcel Pharma Technologies Ltd.	10 percent owner	1 DEXCEL STREET, OR AKIVA L3 3060000